2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection

Srisht Saha, MBBS, MD¹; Raseen Tariq, MBBS²; Ryan Pardi³; Darrell Pardi, MD¹; Sahil Khanna, MBBS, MS¹; ¹Mayo Clinic, Rochester, Minnesota; ²Rochester General Hospital, Rochester, New York; ³University of Minnesota, Minneapolis, Minnesota

Session: 254. HAI: C. difficile - Treatment

Saturday, October 5, 2019: 12:15 PM

Background. Fecal microbiota transplantation (FMT) cures ~90% of patients with recurrent Clostridioides difficile infection (rCDI). Ongoing or repeated exposure to risk factors, especially antibiotics (a modifiable risk factor but often necessary), may lead to future CDI. However, it is not known if FMT provides durable protection against future CDI despite subsequent antibiotic exposure. We studied the long-term durability of FMT against antibiotic exposure post-FMT.

Methods. A retrospective cohort study of patients undergoing FMT via colonoscopy for rCDI from Sep 2012 - Jun 2018 was performed. Patients were followed up for 1 year after FMT; data regarding future CDI episodes (watery diarrhea with positive stool test after interim symptom resolution), healthcare exposure, systemic non-CDI antibiotics and acid blocker therapy were collected. Primary outcome was 'durability' of response to FMT (defined as no CDI within 1 year post-FMT). Descriptive statistics, Chi square test, Wilcoxon test and multivariate logistic regression were used as appropriate.

The study included 460 patients; median age 57 years (range Results. 18-94 years), 65.2% (300) female. Overall 31.6% (144) received antibiotics; median number of courses of antibiotics, 2 (range 1-7). Of those who received antibiotics, the incidence of future CDI was 24.3% (n = 34), compared with 9% (n = 28) of those who did not receive antibiotics (P < .001). Median time to first CDI episode post-FMT was 103 (range 5-338) days. Incremental antibiotic courses did not lead to increased risk of future CDI (comparing 1, 2 or ≥3 courses, p = .68). In patients with antibiotic exposure, age and risk factors were similar in patients with and without future CDI (Table 1). Amongst those without antibiotic exposure, inflammatory bowel disease (IBD) predicted future CDI (p = .02). After controlling for risk factors and comorbidities, antibiotic use (p = .004) and IBD (p = .02) independently increased risk of future CDI.

Conclusion. The majority of patients with rCDI have a durable response to FMT despite ongoing risk factors. These data suggest that three-fourth of patients who receive antibiotics after FMT do not develop future CDI. IBD and antibiotic exposure independently increase the risk of future CDI.

Table 1: Comparison of patients with and without future CDI in those receiving antibiotics post-FMT (n=144)

	Without future CDI	With future CDI	P value
	% (n)	% (n)	
Age	59 (23-94)	58.5 (22-90)	0.29
Sex female	66.0 (70)	58.8 (20)	0.44
Number of antibiotic courses	2 (1-7)	2 (1-7)	0.64
Acid blocker therapy	42.5 (45)	38.2 (13)	0.66
Healthcare exposure	100 (105)	100 (33)	-
Liver disease	17.9 (19)	32.4 (11)	0.07
Cancer	17.9 (19)	11.8 (4)	0.39
Dialysis	6.6 (7)	11.8 (4)	0.33

Disclosures. All authors: No reported disclosures.

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients

Ana D. Vega, PharmD¹; J. Kristie Johnson, PhD, D(ABMM)²;

Emily Heil, PharmD, BCIDP³; Alison L. Blackman, PharmD⁴

Mary Banoub, PharmD⁵; Teri Hopkins, PharmD, BCIDP, BCPS⁶; Surbhi Leekha, MBBS, MPH7; Kimberly C. Claeys, PharmD4; 1Jackson Health System, Miami, Florida; ²University of Maryland Dept of Pathology, Baltimore, Maryland; ³University of Maryland School of Pharmacy; University of Maryland Medical Center, Baltimore, Maryland; ⁴University of Maryland School of Pharmacy, Baltimore, Marvland: 5University of Marvland Medical Center, Baltimore, Marvland; 6South Texas Veterans Health Care System, UT Health San Antonio, UT Austin College of Pharmacy, Baltimore, Maryland; ⁷University of Maryland Dept of Epidemiology and Public Health, Baltimore, Maryland

Session: 254. HAI: C. difficile - Treatment

Saturday, October 5, 2019: 12:15 PM

Background. Molecular strain 027/NAP1/BI (NAP1) is a common cause of Clostridioides difficile infections (CDI). Despite high morbidity and mortality, optimal therapy remains elusive. There is also a paucity of data regarding optimal treatment of critically ill patients with severe CDI. We aimed to determine the impact of combination therapy (intravenous metronidazole [IV MTZ] plus oral vancomycin [PO VAN]) on clinical outcomes in critically ill patients with severe CDI, including those with NAP1 CDI.

Methods. Retrospective cohort of adult patients admitted to an intensive care unit (ICU) from April 2016 to October 2018 with a positive C. difficile PCR and an order for PO VAN. Patients with an order for IV MTZ for at least 72 hours formed the combination therapy group. A subset of patients had stool samples collected for NAP1 identification via GeneXpert C. difficile Epi molecular assay. The primary outcome was 30-day in-hospital mortality. A subgroup was matched using Acute Physiology and Chronic Health Evaluation (APACHE) II Scores. Cox regression was conducted to identify variables associated with time to mortality.

Results. 138 patients were included; 60 (43.5%) received IV MTZ. Patients with IV MTZ had a higher median WBC count at diagnosis (20.9 vs 15.9, P = 0.0002) and were more likely to receive a higher dose of PO VAN (31.7%) vs 12.9%, P = 0.008). 42 patients had NAP1 testing, 11 were positive (26.2%). There was no difference in probability of receiving IV MTZ based on APACHE II, however, NAP1+ were more likely to receive IV MTZ (50% vs 16.7%, P = 0.049). Clinical success was higher in the monotherapy group (46.8% vs 16.7%, P = 0.002). There was no difference in mortality (20% vs 14.1%, P = 0.368). In a subgroup of patients matched by APACHE II (n = 96), mortality remained non-significantly different (18.8% vs 14.6%, P = 0.785). Adjusted for IV MTZ, APACHE II (aHR = 1.06, 95% CI 1-1.12) and number of severity criteria (aHR = 2.08, 95% CI 1.40 - 2.97) were associated with mortality. There was no difference in mortality (9.1% vs 3.2% P = 0.459) or clinical success (18.2% vs 33.7%, P = 0.283) among NAP1+ vs. NAP- patients.

Conclusion. Our data questions the utility of IV MTZ with PO VAN for ICU patients with severe CDI, including NAP1 infections. There remains a possibility for confounding by indication in our analysis.

Disclosures. All authors: No reported disclosures.

2434. Proton Pump Inhibitor Use on Efficacy of Fecal Microbiota Transplant Administered by Trans-Oral Routes for Clostridioides Difficile Infection: A Systematic Review and Analysis

Annie S. Hong, MD¹; Wen Yuan Yu, DO¹; Jenny M. Hong¹; Mohamed Azab, MD²; Gordon V. Ohning, MD, PhD¹; Mahendran Jayaraj, MD¹; ¹University of Nevada Las Vegas School of Medicine, Las Vegas, Nevada; ²Loma Linda University School of Medicine, Loma Linda, California

Session: 254. HAI: C. difficile - Treatment Saturday, October 5, 2019: 12:15 PM

Background. Current guidelines include fecal microbiota transplantation (FMT) in the management of recurrent Clostridioides difficile infections (CDI). However, FMT protocols are often facility dependent, and one variable is whether proton pump inhibitors (PPI) are given during preparation. Theoretically, PPIs reduce acidity and protects the transplanted microbiome for the most potent dose. On the other hand, PPIs have also been shown to negatively alter the microbiome and increase the risk of CDI. We conducted a systematic review of the literature to study PPI use on the efficacy of FMT delivered by the trans-oral route.

Methods. We searched PubMed/Medline, Cochrane Library, Embase, Scopus, and Web of Science through December 16th, 2018 using variations of keywords "fecal microbiota transplant" and "Clostridium difficile infection" with 4210 results. Two independent authors reviewed and excluded studies with unrelated topics, abstracts, case reports, or a low level of evidence. Studies with data on trans-oral FMT, PPI use, and the success rate were included. Final review yielded 11 studies including randomized controlled, case-control, cohort, retrospective and prospective trials. The primary outcome was the rate of FMT failure, defined as recurrence of symptoms with positive CDI testing at follow-up.

Results. Out of 233 included patients, 131 received a PPI per FMT protocol resulting in 27 cases of treatment failure. There were 23 cases of recurrence out of 102 patients who did not receive pre-FMT PPI. The primary outcome occurred in 20.6% in the group with PPI use vs. 22.6% in the group without (RR 0.91; CI 0.56 - 1.50). Limitations include the lack of studies directly comparing outcomes with respect to PPI use, and inability to control possible confounders such as chronic PPI use, amount of stool transplanted, and pre-FMT antibiotics.

We did not find a significant difference in efficacy between FMT Conclusion. protocols with regard to PPI use. It is possible that the theoretical benefit from increased survival of transplanted microbiota is offset by negative effects associated with PPIs. We suggest that routine use of PPIs in FMT be reconsidered in the absence of clear benefit. Further investigation is needed to optimize protocols for safety and efficacy.

	WITELE	TITLE .	NEW M	*****	1175.68	NCORENG	LOCATION	NALESS	OCCUBENCE	ounce		FROM OF	muse	RUMOR LTR	ABREARIES BER	SCHOOL OF	POLLOWAR	Zonato C	Apr	PARENTS	A BOCK-	AREACE.	-
PRICES	-	Recurrent Christialium Affairla orders came series areabring 18 patients treated with Jones stard elementation of case assessment in Mar-	Chesal Inforture Dessen To efficie pathonics of the Inforture Dessen Society of Station	200	Adequates	Maral I Sachaling witarion.	B-Mary's Daladi Class: Baddi weisen, Messiweis, United Rates	June 1996 - Regioni 240	53	particle of sectors.	1. State	Teach	TED 20 mg	~	View 201 or uP3 1-6 days	Na salamana within 19 days	Water	12/1993	Window 71.3 (63-80)	*	1	s.2Ps	1 death Brow partnessin, 51 PMT career B cartholid
	-trainer	And anothers transformation interaction in parameter and transmission provided parameter single-constructions	Paraplast Infectious (Nacas	247	Advergention case when	Newsonie Officiale Science &	Fange Second Report, Flatch, United States	Mag (Kitt) Katalan (Kit		Conducted	1384	Angela	TES. Interpreter M reporting Post and Interpret	**	Vacantica repport a loss (Nitropatar) a reg leperarede	Roshter of Archer compand to backing for a loss 8 works	a works	10.74	Vide II		3	5.85	
	Colors	A Record of Comprises of Read Microbial Transformation Wildow for Reconnect Training Wildow Information	head Method Association Journal	20.4	Adreputive care artist	Marai I Dechalog witerion montaineet	Ld Anto Assession Mindual Context and Rised and Context Mindual Context.	haly 3411 - Regard 3118		minut ad unstand	Lippe and	fram	123. PPL prov monthly below and monthly of the	*13	Agreerian abs	No scaneno e 3 mento	i mente	law	(JAND)	1	1	2.05	There bell
	Frees	hilid operans with load excelors transferration is Chartelan Afficia informer transferrational and performery maths	Ronina Espansis de Enformadados Pigoninas	20.5	Autospulies cost adap	Matal 4 (including scitution, scottainmont)	Castor hogstafer who Noves & pass capitales Autogal	Date 2016 - March 2013		Undered	Copy and	field	TES potents 40.5 conting factors and mercing of	×	Continue whichchurg alter partoneoly on well (Infra- hurless FWT	No toppone within 2 months	2 months	*(8.70	Winham 71 (58-54)	1	1	17.895	
	Relgades	And ministers samplaments for numeror/barahan-difficite activities Experience present, and respla-	Review Expensis de Distantempte : Publication Infant de la Nacional Expensis de Octomorroyale	2014	Propurise one artist	Maral 1 Including withring	Rogital General Universitatio Geografic Wandshite Resea	Auto 2010. Auto 2017		Coperitor	Approxisi tone and will	Auch	115 Hog menaticity before	~	Appropriate offit, dir at local offites below precedient	Routoine of durbos na transrena within 2 mmlh after 1541	2 march	lience	Window TA.A. Tecan W.A	*	1	8 mm	Aut out
		And monitory templatistics for recurson Controllars difficies articulars report on a part series.	launde	26.3	Adaptation constantion	Maral I Delating with time	Economic basish debelli climic methodowine MAV and methodowine W1, Classed Status	Densery 2001 - December 2010		Robert	1.0pm	BOTH: mail Book. 1 Image	1976, sight before and memory of	-	Van 24.00 s. 11 des	No sources within Mildon	N' dep	UCM III	Holard) (199			26.7%	
	Transpire	f and anothing transform for stepping chaindraw difficult anticities using a frame inscalar from another dearm. A resolution open-label, controlled plat study	Cheral Melsiner Neuros	26.4	Reducted	Newcastle Officiale Security	Wannelbandte General Progenel, With, Cannol States	Personal and State	1.8	Cuchead	t ppr and	frant	185- Snyhytherep is Ning integratek for ill bis plar	8	Appropriate sitte, di at ficant sitter: factore	t Tental readation of deathers off dat without schiper within It tents	Paulo	1 CHIPO	Nue 164 30 (15)	*	4	4005	
il al.												_					_		-	14	10	ALC: N	
PPE SUIT	Carboy	Reals of land door initiation frame for recurst Contriduce Official associated displayers	Randow in Instal IV Infertime Disease	20.0	Autospectra case actor	Maral I (including schutters, econtainment)	Contraction lags Monatory of estimate langehol. Names	1991 248		Related	Copy and	-	80		Motor or Varu and reductors of graphesis, org-proving factors	No farther present with longitud for incomposing (CDVD) completion within 80 data of provider)	Water	Test 2114 ctho	Non 13	*		2.00	
	ran Branks	Complexion, effectionen, and long-sem lefters op of load microlinia transfer by teachedinal lefte for instrument of recorrest Chestellane definition with the	Valuel European Gamemenings Immal	243	Amoputie our artis	Marah I Sachaling Withtion associationsmith	Acatomic Medical Comer, Advantation	July 3804 - January 2004	1.00	antini ad uncleal	1.004	freed	-	~	view 201000 s Edecand hored langer	Na souriese videa Il narda	Paulo .	(Linear)	Mindon 10 (1147)		1	1.00%	
	ran Yanati	Decienal inflation of down large for required closettichum difficily	New England Instant of Medicine	20.3	Properties reducted other and	Noncardo Digeo Trans I	Acabero Melical Conte: Assessedant	April 2019		Contend	C)que	Test .	30	20	Vacantial attactual regimes 500 (0071.4.5.days	No scarono vidio 12 water	Hwada	KORPO.	Madan 73 (40-96)		2	19.4875	
	Čeo –		1	20.8	Concentred	Noncardia Milana Second B	Ross of Water Rospitel, thing Kong	Smark 201 Swaite 308	Unputed	Rebeat	£384	nut	80	8	Vacueratie 5 des prise	Albeing of dathers of appleballity after classical bill begative datified for 118	1)-3i eada	300,750	Wadae () (5-56)	•	2	00.0%	

Disclosures. All authors: No reported disclosures.